Endocyte Inc was incorporated in the State of Indiana in 1995 and was reincorporated in the State of Delaware in 2001. The Company completed its initial public offering on April 2, 2014. The Company is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging agents. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore likely to benefit from treatment. Its SMDC candidate, vintafolide, targets the folate receptor, which is frequently over-expressed on cancer cells. The Company's SMDC Pipeline products include Vintafolide designed to deliver a cytotoxic drug payload directly to folate receptors that are over-expressed on cancer cells, with low toxicity to healthy cells; EC1456 is a second generation folate receptor-targeted SMDC. It is a conjugate of folate and an anti-cancer drug payload of tubulysin, a microtubule destabilizer; EC1169 is non-folate targeted SMDC and is designed to specifically target PSMA; EC1788 is a folate receptor-targeted SMDC in preclinical development with a very potent DNA alkylator drug; EC1669 is a folate receptor-targeted SMDC in preclinical development for treatment in inflammatory diseases; and EC0371 is a folate receptor-targeted SMDC in preclinical development for treatment of polycystic kidney disease. The Company faces competition from other pharmaceutical companies, biotechnology companies, public and private universities and research organizations. Government authorities in the United States (including federal, state and local authorities) and in other countries regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, distribution, post-approval monitoring and reporting, advertising and promotion, and export and import of pharmaceutical products.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.